Author: Becks Stratton

18 August 202618 August 2026 by Becks Stratton

New Zealand Standards for Urine Drug Testing: AS/NZS 4308:2023 Guide

A deadline is approaching that many New Zealand employers don’t yet know about, and those who miss it will find themselves in a very uncomfortable position.

By November 2026, every workplace drug testing programme in the country will need to meet the updated requirements under the AS/NZS 4308:2023. The standard is officially called: Procedures for Specimen Collection and the Detection and Quantification of Drugs in Urine.

It doesn’t matter whether you’re a civil contractor in Canterbury, a forestry company in Rotorua, a transport operator in Waikato, a dairy processor in Southland or a manufacturing business in Auckland; if your workplace carries out urine drug testing, the November 2026 deadline applies to you.

AS/NZS 4308:2023 sets out how urine drug testing should be carried out, employers also need to ensure any testing programme aligns with their obligations under New Zealand’s Health and Safety at Work Act 2015, employment law and their own workplace drug and alcohol policy.

Sober Check has put together this guide to help to break it all down.

What Changed from AS/NZS 4308:2008 to 2023

The AS/NZS 4308 standard had been around since 1995, originally published as AS 4308-1995, and New Zealand workplaces built their drug-testing programmes around it. In 2001, it was revised and jointly designated as AS/NZS 4308:2001. In 2008, it was updated as AS/NZS 4308:2008, which introduced provisions for on-site screening. In 2023, the standard was updated to AS/NZS 4308:2023. It included a 36-month rollover period before the 2008 standard was to be superseded. This gives everyone involved in the process time to update policies, procedures and products.

The AS/NZS 4308:2023 standard enhances workplace drug testing by lowering cut-off levels for cocaine and updating reporting terminology to “not-negative.” Science has moved forward, substances have evolved, and the 2008 standard simply couldn’t keep pace with what employers were actually dealing with on-site, in the real world.

The 2023 revision, however, brought the standard into the modern era across several key areas:

The scope of substances screened for was only slightly altered (with only cocaine changing). The updated standard now better accounts for the realities of contemporary drug use, with some of the key findings below:

There is a whole new appendix dedicated to Additional and optional testing – Appendix A, which covers Additional and optional testing, including setting a cut-off level for Oxycodone if it is included in a screening test.
Cut-off levels for specific drugs and compounds, depending if you are using:
immunoassay – a biochemical test that measures the presence or concentration of a substance (analyte), including drugs, in biological samples using the specific binding between an antigen and an antibody

mass-spec screening – a highly specific analytical technique used to detect and quantify compounds, such as drugs, by sorting ions based on their mass-to-charge ratio.
It also gives a list of examples of drugs that can be tested for in consultation with a lab, such as Fentanyl and Synthetic Cannabinoids.

Collector training and competency requirements also saw meaningful updates. The standard places a strong emphasis on the qualifications of the people who are actually administering collections, not just on the labs that process the samples. That’s a change that matters a lot for employers who are increasingly relying on on-site testing programmes. Sober Check’s NZQA-aligned training helps organisations ensure collectors understand both the technical requirements of AS/NZS 4308:2023 and the practical responsibilities involved in specimen collection.

Point-of-care testing devices (such as rapid on-site screening kits) are addressed with greater specificity than before. The criteria for acceptable devices, their proper use and the handling of results have all been clarified. This should be genuinely helpful for anyone trying to run a compliant on-site programme.

Stronger Quality Control Requirements for On-site Testing

One of the biggest operational changes introduced in AS/NZS 4308:2023 is the increased emphasis on quality control for on-site urine drug screening.

Under the previous 2008 standard, much of the quality assurance focus sat with accredited laboratories. The 2023 standard places greater responsibility on organisations that conduct workplace testing themselves by introducing defined quality-control procedures for on-site screening devices and for creatinine measurement.

This means employers can no longer simply purchase compliant urine drug testing devices and assume they remain compliant throughout their shelf life.

The testing programme itself must demonstrate that devices continue to perform as intended. The new quality control requirements include:

High-and low-control samples must be tested before a new lot of on-site drug-screening or creatinine-testing devices is put into service.
Ongoing high- and low-control testing must then be performed at least monthly for every lot of devices held in storage.
All quality control results must be documented and retained as part of the organisation’s quality records.
If a control test fails, the affected lot must be investigated and, where necessary, withdrawn from service until satisfactory performance has been demonstrated.
Organisations must also have documented procedures describing how quality control failures are managed and how the integrity of previous test results will be assessed if a failure occurs.

The standard also encourages participation in ongoing proficiency or blind testing programmes. These independently verify that collectors, devices and on-site testing processes continue to produce reliable and repeatable results over time rather than simply relying on manufacturer specifications.

For employers running their own workplace testing programme, this represents a significant shift. Compliance is no longer just about using the right urine cup or following the correct collection procedure. It now includes maintaining documented evidence that the testing devices themselves continue to perform accurately throughout their use.

For many organisations, this may mean introducing monthly quality control testing that wasn’t previously documented, keeping records of lot verification and ensuring expired devices are removed from service.

If you’re unsure whether your current testing devices meet the new requirements, Sober Check can help review your existing programme and recommend independently verified products that comply with AS/NZS 4308:2023.

New Cut-Off Levels and Detection Windows

Cut-off levels are the concentration thresholds that determine whether a sample returns a not-negative or negative result. Get them wrong (or use outdated thresholds) and the whole testing programme is built on shaky ground.

AS/NZS 4308:2023 has seen the following key changes implemented:

Key Changes in Cut-offs (2008 vs. 2023):

Cocaine Metabolites: Screening reduced from 300 ng/mL to 150 ng/mL. Confirmation dropped from 150 ng/mL to 100 ng/mL.
Benzodiazepines: Screening remains at 200 ng/mL, but the confirmation cut-off for metabolites (Nordiazepam, Oxazepam, Temazepam) has been revised to improve accuracy and reduce false positives.
Opiates, Amphetamines and THC: Cut-off levels for these substances remain consistent with the 2008 standard.

These changes across the substance classes are to better align with both current pharmacological understanding and international best practice. This matters in practice because a test calibrated to old thresholds might clear someone who shouldn’t be cleared or flag someone who shouldn’t be flagged.

Cannabis remains the most commonly detected substance in New Zealand workplace urine testing. Detection windows vary based on factors such as frequency of use, body composition, and the type of specimen collected. On that last note, urine is the most common specimen.

For amphetamines (including methamphetamine), the cut-off levels have not changed. A urine test identifies previous drug use rather than current impairment. Employers should understand the limitations of urine testing and ensure it forms part of a wider fitness-for-work programme, supported by clear workplace policies and appropriate decision-making processes.

Cocaine and some specific analytes for other drug classes have updated cut-off levels under the 2023 standard. If you want to test for compounds outside the ‘standard six’ (opiates, amphetamines, methamphetamine, cocaine, benzos & THC), you can use extended panel testing, such as a dip test; however, the standard notes that it should be done in consultation with a laboratory that can provide advice on what levels are consistent or inconsistent.

Any testing programme still operating off 2008 cut-off numbers needs to be updated immediately.

Not in November 2026, but now.

What is Creatinine?

Creatinine is a naturally occurring chemical waste product generated by muscle metabolism and filtered exclusively by the kidneys, which excrete it into urine. In a healthy human body, muscle mass and kidney function remain relatively stable day-to-day, so creatinine concentrations in normal urine remain within a highly predictable, consistent baseline range.

Why is it a Critical Focus in Workplace Drug Testing?

Creatinine testing helps determine whether a urine sample is likely to be genuine and suitable for testing. Extremely low creatinine levels may indicate an excessively diluted sample or possible substitution, while abnormal results prompt further investigation in accordance with workplace procedures.

Because it is an unavoidable biological signature of human urine, tracking creatinine allows testing officers to immediately identify if a donor is attempting to cheat or tamper with the test.

Testing panels look for two major red flags:

The Absence of Creatinine (Low Readings): An abnormally low or completely absent creatinine reading indicates that the sample is not a natural human specimen. It instantly flags that the donor has either substituted their sample with synthetic “fake urine” or has consumed extreme volumes of water to flush and dilute their system below the readable drug thresholds.
Spiked Concentrations (High Readings): Conversely, an unnaturally elevated or concentrated creatinine reading suggests that it might be a heavily diluted or altered sample.

The AS/NZS 4308:2023 Enforcement

While modern urine cups utilise a matrix of integrity checks – including pH scales, specific gravity, and temperature strips (which have been expanded under the 2023 standard to read from 32°C to 38°C) – the new standard singles out creatinine for rigorous enforcement.

Under the AS/NZS 4308:2023 regulations, creatinine testing panels can no longer be passive add-ons. Manufacturers must be able to demonstrate that their devices have been independently verified as fit for purpose in accordance with Appendix B of AS/NZS 4308:2023. In addition, organisations conducting on-site testing must now perform ongoing high- and low-creatinine quality control testing to verify continued device performance.

Chain of Custody Requirements

Chain of custody is where a lot of well-intentioned drug testing programmes quietly fall apart. It sounds like a legal formality, but it’s actually the backbone of any defensible result.

If a positive test ever ends up in a hearing or an internal dispute process, chain-of-custody documentation is what makes or breaks the case.

AS/NZS 4308:2023 reinforces and clarifies the chain of custody requirements present in the 2008 standard, with greater specificity regarding documentation, handling and transfer procedures.

From the moment a specimen is collected, every step needs to be documented. Who collected it, when, reason for testing, unique donor identifiers, screening results (if the sample is screened), and donor acknowledgement that the sample is theirs. All of it needs to be traceable without gaps.

The standard specifies the use of tamper-evident specimen containers and requires that chain-of-custody forms accompany specimens throughout the process.

For on-site testing, chain-of-custody requirements also apply to the screening process. A not-negative screening result that isn’t properly documented and handled in accordance with the standard cannot be relied upon if challenged.

That’s a very real risk for employers who treat on-site testing as a quick, informal process rather than a documented procedure. Laboratories may also refuse to run tests on samples that do not meet the chain-of-custody protocol.

Employer Compliance Checklist

Getting compliant with AS/NZS 4308:2023 isn’t a job to put aside for an afternoon; however, it is absolutely manageable with the right roadmap.

Here’s what every employer should be working through before that November 2026 deadline:

Review and update the workplace drug and alcohol policy: The policy needs to reference the current standard, not the 2008 version. If the document still cites AS/NZS 4308:2008, it needs to be updated.
Audit current testing procedures against the 2023 requirements: Cut-off levels, collection procedures and documentation practices are all ways to compare what’s happening on the ground with what the standard actually requires.
Verify laboratory accreditation: Working with accredited partners who understand New Zealand workplace drug testing legislation is important.
Check the collector’s qualifications and training: The people administering collections need to meet the competency requirements outlined in the 2023 standard. Review their credentials and identify any gaps.

Sober Check Training is a registered Private Training Establishment (PTE) delivering NZQA unit standard based urine drug testing training, helping collectors develop the competency expected under AS/NZS 4308:2023.

Review on-site testing device compliance: If rapid on-site screening devices are part of the programme, confirm they meet the performance criteria specified in AS/NZS 4308:2023.
Update chain-of-custody documentation: The forms, procedures and handling practices will all need to align with the current standard’s requirements.
Train managers and supervisors: The people making reasonable-cause testing decisions need to understand what the updated standard means for their roles and take refresher training if needed. Sober Check also offers refresher training and recommends doing this every three years.
Implement an on-site quality control programme: If your organisation conducts on-site urine drug testing, ensure routine high- and low-control testing, lot verification, documentation, and quality control procedures comply with AS/NZS 4308:2023.

What Happens If You’re Not Compliant by the November 2026 Deadline

Here’s the uncomfortable part. A drug testing programme that doesn’t comply with AS/NZS 4308:2023 after the November 2026 deadline isn’t just technically out of date. It also creates genuine legal and operational exposure.

In safety-critical industries where drug testing is a regulatory requirement, non-compliant testing procedures can undermine the legal defensibility of results. An employee who is dismissed following a positive result from a non-compliant test has very real grounds to challenge that outcome. And, depending on the nature of the workplace, this can affect employment or health and safety proceedings. Beyond the legal risk, there’s a practical safety argument. The 2023 standard exists because the 2008 standard wasn’t keeping pace with the actual landscape of workplace drug use. Operating under outdated cut-offs and procedures means the testing programme may not catch what it’s supposed to. It’s not necessarily drugs at the workplace; it’s about not being at work while impaired, thereby increasing the risk of an unsafe work environment. That risk ultimately shows up as workplace incidents, not compliance notices.

The November 2026 deadline feels like it’s a long way off. It isn’t. Updating a workplace drug testing programme (and especially in a large organisation) takes time. Policy reviews, supplier conversations, staff training and documentation overhauls are each significant processes. Getting each process underway now is the move that makes the deadline feel manageable.

Leaving it for late 2026 is precisely the kind of move that could make it feel like a crisis!

Are you ready to make sure your workplace drug testing programme meets every requirement under AS/NZS 4308:2023?

Preparing for AS/NZS 4308:2023 isn’t just about meeting a deadline. It’s an opportunity to review your entire workplace drug testing programme and ensure your policies, procedures, training and testing devices continue to support a safe workplace.

Whether you’re updating an existing programme or implementing workplace urine drug testing for the first time, Sober Check can help you understand the requirements of the new standard, select independently verified testing devices and provide NZQA training for your collectors.

Get in touch with the team today to learn how we can help get your testing programme in place.

09 April 202610 April 2026 by Becks Stratton

Q&A with Louis Foster (CEO, Sober Check)

“Helping People Help People”: The Philosophy of Modern Site Safety

Interviewer: Louis, you’ve recently formalised your internal purpose as “Helping People Help People.” That sounds more like a non-profit mission than a drug-testing company. Why that specific phrasing?

Louis Foster: It’s because I believe that it’s a reflection of what we actually do on the ground every day. Here at Sober Check, it isn’t just about shipping boxes of plastic cups to our clients, we’re thinking about the end user at each stage. We are empowering a Site Manager to ensure their team goes home at night. We are helping a Recruitment Consultant place a driver in a large machine, confident they aren’t impaired.

When you look at a client like a District Health Board or an addiction treatment centre, “Helping People Help People” is literal. We provide tools such as the OneScreen 10 urine kit or the Lifeloc breathalysers that allow a clinical practitioner to guide an addict back to sobriety. We provide the “objective truth” in a situation where people are often struggling and looking for a way out. Our purpose is to be the reliable foundation that these “helpers” stand on.

Interviewer: You mention “Objective Truth.” How do you address the sceptics who say drug testing is just a punitive “Gotcha” game for workers?

Louis Foster: That is a misconception we work hard to correct. Modern workplace testing isn’t about questioning employees about what they got up to over the weekend, outside of work. It’s more about discerning how these choices might present as a safety risk on the worksite on a Monday morning. Alcohol is still the most prevalent drug of abuse because it’s legal and accessible. But unlike THC in a urine test – which might stay in your system for weeks – alcohol testing correlates much more closely to impairment.

We promote the Lifeloc LT7 precisely because it gives a qualitative positive or negative result and can be followed up with a quantitative level result. It’s verified to the 2019 standard, is a high-quality and accurate unit that managers can rely on. So it’s not a “guess.” It tells the HSEQ manager: “This person is currently a risk to themselves and others.” We aren’t the “Drug Police”; we are the “Safety Guardrails.” By identifying a risk early – whether it’s hydration, alcohol or meth – we are preventing a tragedy, not just enforcing a policy.

Importantly, I really want to mention that it doesn’t matter if the substance or thing you’re taking is legal, prescribed, illegal or recreational. Whatever it might be, it is a simple question that needs to be answered; what safety risk does it create and how is it being addressed. This is why it’s not about playing ‘gotcha’ with employees who are being drug tested. It’s about how to minimise risk in the workplace through a process-driven mitigation strategy.

Interviewer: Western Australia is a major focus for Sober Check. What are the unique challenges of the WA market, especially regarding “Lizard Urine” and sample tampering?

Louis Foster: (Laughs) The “Lizard Urine” problem is real. On a FIFO site in the middle of nowhere, there is a lot of pressure to “pass” a test. We’ve seen everything from people taping bladders of fake urine to their inner thighs, or trying to microwave samples to hit that 32–38°C range.

This is why our training and our products are also focused on Adulterant Detection. Our Medix ProSplit and SCOUT Scan urine drug screen cups include panels that show “indicators of cheating” such as pH levels, nitrates, and creatinine. If someone is a “lizard” or has a fever, our cups catch it instantly. We educate our clients that “observed testing” or “oral fluid” is often the best defence against this. While observed urine testing must meet strict privacy-versus-safety risk thresholds, an oral fluid test like the STEALTH Flow, can be conducted right in front of you, making it very hard to tamper with covertly.

Interviewer: How has the Iran conflict and the subsequent oil shock changed the conversation around workplace safety for your clients?

Louis Foster: When margins are thin and fuel is costing $3+ a litre, the cost of a “total loss” incident on a mine site or a construction zone is catastrophic. If someone is injured, or worse, killed, because an impaired driver fell asleep or lost concentration due to dehydration, that could bankrupt a subcontractor in this economy.

We are seeing clients move toward a “Workplace Wellness” model. They aren’t just doing “Drug Testing”, they’re doing “Holistic Health Monitoring.” This includes hydration testing with the MX3 and wellness testing, such as cardiac markers with the i-Stat device. If you can spend $15 on a test to prevent a multi-million dollar tragic incident, that’s just good business. In a recessionary environment, “zero harm” is a financial imperative, not just a CSR slogan.

Interviewer: You’ve spoken about the “ED Triage” application of the OneScreen 10. That seems a long way from a mine site.

Louis Foster: It’s actually where our work becomes most “purposeful.” This solution applies particularly to acute inpatients or detox units, once an overdose patient becomes conscious, but time is still critical in terms of assessing the nature of any drug-induced effects and clinicians don’t have time to wait 24 hours for a lab report.

Using OneScreen 10, they can get an instant screen for the “Big 10”, which includes Methadone and Oxycodone. If the person is severely impaired, the ED doctor can immediately suspect something like GHB or GBL, which don’t show up on standard screens but have very specific treatment protocols. That 60-second test can guide a life-saving medical intervention. That is the ultimate example of “Helping People Help People.”

Interviewer: Finally, what is the “Louis Foster” vision for Sober Check in Australia over the next two years?

Louis Foster: We want to be the partner of choice for employers across Australia and New Zealand, bringing real solutions and understanding to your D&A programme and enhancing workplace safety in both countries.

We will continue to build our Sober Check Brands to control quality and pricing for our clients. We will lead the market on the 2023 Standard transitions. But ultimately, we want to be known as the team that actually cares about the person at the end of the swab. We want to make Australasian workplaces safer, one objective result at a time.

17 March 202618 March 2026 by Becks Stratton

Drug Testing at Mine Sites: How it Underpins Site Safety

Australian mining operates in one of the most high-risk industrial environments in the country. Employing more than 300,000 Australians in remote and hazardous locations, the sector depends on precision, coordination and constant situational awareness to operate safely.

Explosives handling, heavy fleet movement, underground operations and underground and open-cut operations create an extremely narrow margin for error across daily shifts.

In this environment, impairment caused by drugs or alcohol is not a minor concern but a direct and immediate threat to life. For modern operators, mining safety Australia begins with ensuring every worker is genuinely fit for duty before stepping onto site and commencing high-risk tasks under strict procedural controls.

Beyond the Law: The Moral Case for Testing

While regulatory compliance is essential, drug and alcohol testing in mining goes far beyond meeting legal obligations. As highlighted by AusHealth, testing should never be viewed as punitive or designed to catch people out after mistakes occur. Instead, it is a preventative safety measure that protects workers, contractors and surrounding communities before incidents happen. When incidents occur on mine sites, the consequences extend well beyond operational disruption or production delays. Families, colleagues and regional communities often carry the long-term emotional, social and economic impacts of serious injuries or fatalities that could have been avoided through earlier intervention.

Shifting from a blame-based mindset to a care-based safety culture reframes testing as a support mechanism rather than a disciplinary tool used after harm occurs. It signals that employers are committed to Zero Harm, recognising impairment risks early and intervening before accidents occur. This approach strengthens trust between workers and management, reinforces shared responsibility for safety outcomes and aligns with contemporary expectations of ethical leadership across the Australian resources sector.

The FIFO Factor: Mental Health and Substance Use

The structure of modern mining work presents unique challenges that increase the risk of substance misuse. Fly-in, fly-out arrangements, extended rosters, compressed work cycles and prolonged isolation from family and social support networks place significant psychological strain on workers. Research indicates that approximately 20% of the mining workforce experiences psychological or social difficulties linked directly to these conditions and work patterns.

These pressures are reflected in substance use data. Alarmingly, 45.7% of males working in coal mining report risky or hazardous drinking behaviours during off-shift periods. Fatigue, loneliness, disrupted sleep and cumulative stress can compound decision-making impairment, especially when combined with alcohol or drugs. A well-designed FIFO drug and alcohol policy acknowledges these realities and integrates testing with education, mental health support, fatigue management and early intervention strategies rather than relying solely on disciplinary responses.

Regulatory Framework: Navigating State and National Laws

Drug and alcohol testing at mine sites is firmly embedded within Australia’s work health and safety framework. At a national level, the Work Health and Safety (WHS) Act 2011 imposes a duty of care on employers to take all reasonably practicable steps to eliminate or minimise risks, including impairment-related hazards. Failure to manage fitness for work can expose Site Senior Executives to significant legal, financial and reputational consequences under enforcement action.

State-based regulations reinforce this obligation. In Western Australia, the WHS (Mines) Regulations 2022 explicitly require mine operators to manage hazards related to alcohol and other drugs. Queensland’s Coal Mining Safety and Health Act 1999 mandates that workers must be fit for work at all times, while New South Wales’ WHS (Mines and Petroleum Sites)Regulation 2014 places similar expectations on duty holders. Together, these frameworks make drug testing mine sites a non-negotiable element of compliance across all major mining jurisdictions.

Implementation: Best Practices for 2026

As mining operations evolve, so too must impairment management strategies. Best practice for 2026 points toward a blended approach combining random and targeted testing. Random testing acts as a strong deterrent, while targeted testing following incidents or reasonable cause ensures risks are addressed promptly, fairly and consistently. This balance supports operational integrity without creating a culture of surveillance or mistrust on site.

Education and rehabilitation are equally critical. Integrating testing programs with Employee Assistance Programs (EAP) allows workers who return non-negative results to access confidential counselling and treatment pathways. This reinforces the principle that fitness for work mining programmes exist to keep people safe, supported and productive rather than to terminate employment unnecessarily or create fear-based compliance.

Technology also plays a defining role, particularly in remote environments where laboratory access is limited or delayed. Using high-quality, certified testing equipment ensures results are accurate, defensible and compliant with Australian Standards. Providers such as Sober Check supply industrial-grade breathalysers and oral fluid (saliva) drug testing devices designed specifically for harsh site conditions, supporting reliable on-site decision-making. Mining operators can explore these solutions and learn more about Sober Check’s end-to-end safety services.

Conclusion: Testing as the Bedrock of Site Integrity

Drug and alcohol testing is not simply a regulatory checkbox for Australian mining; it is a foundational element of site integrity, workforce protection and operational resilience. While compliance with legislation is essential, a mature safety culture recognises testing as part of a broader commitment to Zero Harm. By addressing FIFO pressures, supporting mental health and implementing robust, fair testing protocols, operators actively safeguard lives, reputations and long-term productivity.

As expectations rise toward 2026, Site Senior Executives and Health and Safety Representatives should proactively review their drug and alcohol policies, testing methodologies, governance processes and equipment standards using contemporary guidance. Investing in reliable technology and professional support strengthens fitness-for-work systems and demonstrates genuine care for people.

Mining organisations seeking guidance or upgraded testing infrastructure are encouraged to connect with Sober Check through their contact channels to ensure their sites remain safe, compliant, resilient and future-ready across all operational contexts nationwide, reinforcing industry-wide accountability.

26 February 20269 March 2026 by Becks Stratton

Workplace Drug Testing in Australia: Trends & 2026 Insights

Introduction: The State of Play in 2026

Workplace drug testing in Australia has become a critical component of organisational risk management as employers respond to evolving substance use patterns and heightened Work Health and Safety (WHS) obligations. According to recent data from The Drug Detection Agency (TDDA), the national workplace drug test positivity rate reached 3.1% in the September quarter. While this figure may appear stable at a glance, it represents thousands of individual safety decisions being made across Australian worksites every week.

Importantly, this data reflects more than isolated incidents. It highlights a sustained post-pandemic baseline in which substance use has become more diversified, socially normalised, and less predictable. Hybrid work models, increased job stress, and blurred boundaries between work and personal time have all contributed to this shift.

As a result, workplace drug testing Australia-wide is no longer viewed as a reactive compliance exercise. Instead, it is increasingly recognised as a proactive safety strategy that protects employees, contractors, business continuity, and organisational reputation.

The “Summer Surge”: Why Safety Doesn’t Take a Holiday

Australian employers face a recurring seasonal risk commonly referred to as the “summer surge.” Analysis reported by Human Capital Australia shows that positive workplace drug tests consistently rise during warmer months, particularly around public holidays, Christmas shutdowns and extended leave periods.

Why Do Drug Tests Increase in Summer?

The Australian “silly season” creates ideal conditions for increased substance use. End-of-year celebrations, social events, and relaxed routines often lead to higher consumption of alcohol and illicit drugs. When employees return to work, residual impairment can still be present, especially in safety-critical roles.

Several contributing factors explain this seasonal pattern:

• Increased social and recreational drug use during holidays
• Longer detection windows overlapping return-to-work periods
• Reduced routine and sleep disruption
• Informal or relaxed management oversight during summer

While goodwill and flexibility are important, WHS compliance requires consistency. Drug testing programs must remain active during peak risk periods rather than being reduced when risk is highest.

The Substance Shift: Beyond the Usual Suspects

Substance use trends in Australian workplaces have shifted significantly over recent years. What was once dominated by a narrow range of drugs has expanded into a more complex and varied profile that affects multiple industries and role types.

The Cocaine Climb

One of the most notable drug testing trends 2026 data has revealed is the steady increase in cocaine detection. Cocaine now represents approximately 8.5% of positive workplace drug tests and is no longer confined to senior or traditionally white-collar environments.

Improved availability, reduced stigma, and expanded distribution networks have contributed to its presence across construction, transport, mining, and professional services. While cocaine is often perceived as a “functional” stimulant, it significantly impairs judgement, increases risk-taking behaviour and elevates the likelihood of workplace incidents.

ATS Dominance Across Industries

Amphetamine-Type Substances (ATS), including methamphetamine, remain the most dominant drugs detected in Australian workplaces. In 2026 data, ATS appear in 53.2% of all positive tests, representing a 6.3% year-on-year increase.

The WHS risks associated with ATS use are severe and well documented. Common impacts include:

• Overconfidence and impaired judgement
• Fatigue crashes following stimulant use
• Increased aggression or agitation
• Reduced risk perception

In high-risk environments involving machinery, vehicles, or complex operational tasks, these effects can be catastrophic. This dominance reinforces the importance of random drug testing workplace programs as a core deterrent strategy.

Cannabis (THC): Presence Versus Impairment

Cannabis continues to be detected in 46.5% of positive workplace drug tests, also increasing by 6.3%. As social attitudes and legislation evolve, employers face ongoing challenges balancing individual freedoms with safety obligations.

The central issue remains the distinction between presence and impairment. THC can remain detectable long after consumption, yet employers must still assess fitness for work based on role-specific risk. Clear policy wording, role-based thresholds and consistent enforcement are essential for managing cannabis-related risk fairly and defensibly.

Fast Facts: Australian Workplace Drug Testing 2026

• Overall positivity rate: 3.1%
• ATS/Methamphetamine: 53.2% of positive tests
• Cannabis (THC): 46.5% of positive tests
• Cocaine: 8.5% and steadily rising
• Opioids: 16% with a gradual decline

Modernising the Policy: Return-to-Work & Random Protocols

Many workplace drug and alcohol policies currently in use were designed for a less complex risk environment. Annual testing or post-incident testing alone is no longer sufficient to meet modern WHS expectations.

In 2026, leading organisations are adopting comprehensive approaches that include:

Structured random drug testing workplace programs
Mandatory return-to-work testing following incidents or extended leave
Clear escalation pathways and documentation
Consistent application across all roles and seniority levels

Random testing acts as a proven deterrent, while return-to-work protocols support accountability, recovery and transparency. Together they form a defensible safety framework aligned with contemporary WHS standards.

Manager capability is equally critical. Leaders must be trained to recognise impairment indicators, understand procedures, and act decisively. The ability to “notice and act” is now a core leadership competency, particularly in safety-sensitive environments.

This is where Sober Check Australia provides value beyond testing hardware, supporting organisations with compliant equipment, practical guidance, and policy-aligned frameworks that help businesses enforce drug and alcohol programs consistently and confidently.

Technical Standards: Oral Fluid vs Urine

Australian drug testing programs must comply with recognised standards. Oral fluid/saliva testing is governed by AS/NZS 4760:2019, while urine testing follows AS/NZS 4308:2023.

Urine testing remains valuable for identifying historical use patterns. However, oral fluid testing is increasingly preferred in 2026 due to its ability to detect recent use, making it more relevant for real-time safety decisions.

Employers can access compliant workplace testing solutions through Sober Check Australia’s range of Drug Testing Kits, Saliva Tests, and Alcohol Breathalysers, designed to support Australian drug testing standards and WHS compliance.

Key reasons for the shift toward oral fluid testing include:

• Detection of recent drug use
• Faster on-site collection
• Reduced privacy concerns
• Greater alignment with impairment risk

Conclusion: Building a Resilient Workforce

Workplace drug testing Australia-wide is no longer about compliance alone. It is about building a resilient, safety-focused workforce capable of adapting to seasonal pressures and evolving substance trends.

As summer approaches and positivity rates rise, now is the ideal time for employers to:

• Audit existing drug testing kits
• Review and update drug and alcohol policies
• Reinforce manager training and accountability
• Ensure alignment with WHS compliance obligations

Organisations that act proactively will be better positioned to reduce incidents, protect employees and maintain operational integrity. To stay ahead of drug testing trends 2026, businesses are encouraged to contact Sober Check Australia today to learn more about compliant testing solutions, policy support and training designed for modern Australian workplaces.